Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth.
PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have
locally advanced or metastatic thyroid cancer that did not respond to iodine therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
AstraZeneca Brigham and Women's Hospital Dana-Farber Cancer Institute National Cancer Institute (NCI)